HONG KONG – Alvogen Korea Ltd. has announced an agreement for exclusive rights to license, sell and market Vivus Inc.'s obesity drug, Qsymia (phentermine/topiramate), in South Korea, a deal expected to shore up the company's strong position in the Korean market while adding to its obesity portfolio, said Petar Vazharov, Alvogen's Asia-Pacific executive vice president.
HONG KONG – Shanghai Fosun Pharmaceutical Group Co. Ltd. has made progress on its proposed purchase of the majority stake in India's Gland Pharma Ltd., with a recent amendment stating it would acquire 74 percent of the interest in the Hyderabad-based pharmaceutical company for $1.09 billion, instead of the original proposed 86 percent for $1.26 billion.
HONG KONG – Alvogen Korea Ltd. has announced an agreement for exclusive rights to license, sell and market Vivus Inc.'s obesity drug, Qsymia (phentermine/topiramate), in South Korea, a deal expected to shore up the company's strong position in the Korean market while adding to its obesity portfolio, said Petar Vazharov, Alvogen's Asia-Pacific executive vice president.
HONG KONG – Chinese biotech company Harbour Biomed Therapeutics Ltd. has entered a collaboration and licensing agreement with South Korea's Hanall Biopharma Co. Ltd. for novel biologics. Under the agreement, Harbour, of Shanghai, will have the rights to develop, manufacture and commercialize HL-161 and HL-036 for the Greater China market, which includes the territories of Hong Kong, Macau and Taiwan.
HONG KONG – Orbimed said it raised around $551 million in its third Asia-focused private equity fund, Orbimed Asia Partners III (OAP3), nearly doubling the $325 million raised for the previous fund in September 2014.
HONG KONG – Orbimed said it raised around $551 million in its third Asia-focused private equity fund, Orbimed Asia Partners III (OAP3), nearly doubling the $325 million raised for the previous fund in September 2014.
HONG KONG – 3Sbio Inc. inked a proposed asset purchase agreement worth $290 million for the contract development and manufacturing organization (CDMO) business of Canada's Therapure Biopharma Inc., a deal that would mark 3Sbio's first foray into the North American biopharmaceutical sector.
